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A CASE STUDY OF CANADIAN REGULATION
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I.

INTRODUCTION

In 2010, Canada became the first jurisdiction in the world to
prohibit Bisphenol A (BPA) in a range of products including infant
feeding bottles.1 Since that time, the European Union has moved to
ban BPA in other materials that come into contact with food and are
intended for infants and young children.2 These jurisdictional
differences reflect the ongoing development of scientific knowledge, as
well as the controversies that continue to rage within the scientific
community, industry, regulatory agencies, and civil society regarding
BPA and other substances that act on the endocrine system. These
substances mimic naturally produced hormones, and in many cases
have been associated with negative health outcomes.3 Given the great
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1. Hazardous Products Act (Bisphenol A), 2010 (SOR/2010-53) (Can.). BPA was also
prohibited in cosmetics, and a range of information-gathering measures and further regulatory
objectives were adopted. For example, certain medical devices that come into contact with
patients or patient fluids are surveyed, and targets for the migration of BPA from food packaging
linings are under consideration. Government of Canada, Risk Management Milestones for
Bisphenol
A,
https://www.canada.ca/en/health-canada/services/chemicalsubstances/challenge/batch-2/bisphenol-a/risk-management-action-milestones.html, (last visited
Feb. 16, 2021).
2. European Commission Press Release IP/11/664, Bisphenol A: EU Ban on Baby Bottles
to Enter into Force Tomorrow (May 31, 2011).
3. Johanna R. Rochester, Bisphenol A and Human Health: A Review of the Literature,
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importance of the endocrine system to humans and other species, the
presence in organisms and ecosystems of substances that interfere with
this system is cause for alarm. However, many such substances are used
therapeutically, including vitamins and the birth control pill.4 The term
endocrine disrupting chemical, or EDC, is generally used to refer to
chemicals that generate negative health outcomes by interfering with
the actions of hormones;5 this is the meaning that we adopt. We focus
on known or suspected EDCs, that is, chemicals whose impact on the
endocrine system is or may be harmful.
This paper’s objective is to shed light on the science of endocrine
disruption, and on the manner in which this scientific knowledge is
taken up and acted upon by regulatory agencies. We will proceed
through a case study of the Canadian regulation of BPA. We seek to
present an accessible yet nuanced and rigorous discussion of the
science of endocrine activity in order to promote understanding of the
Canadian regulatory decision, and to draw attention to the challenges
faced by Environment and Climate Change Canada (ECCC)6 and
Health Canada (HC), as well as regulatory agencies around the world
that seek to understand and react to the risks posed by EDCs such as
BPA. One dimension of this challenge is the state of scientific
knowledge about EDCs. Very little is known about many substances
of potential concern, including other bisphenols that have a chemical
structure very similar to that of BPA. These knowledge gaps are
troubling, not least because structural similarities make these less wellunderstood chemicals good candidates for replacing those that have
been linked to negative health outcomes and have been the object of
public concern and regulatory action. The risk thus arises that
successive replacement chemicals could in turn be revealed to be
EDCs, a phenomenon referred to as regrettable replacement or
substitution.7 In addition to the risks posed to public health, these
regrettable replacements affect public confidence in manufacturers
and regulators, and possibly in public health science. They are not
without risks for manufacturers either, as they must scramble to find
REPROD. TOXICOL. 42, 132-135 (2013).
4. Katherine E Kelley et al., Identification of Phthalates in Medications and Dietary
Supplement Formulations in the United States and Canada, ENVIRON. HEALTH PERSPECT. 120,
379-384 (2012).
5. Evanthia Diamanti-Kandarakis et al., Endocrine-Disrupting Chemicals: An Endocrine
Society Scientific Statement, ENDOCR. REV. 30, 293-342 (2009).
6. At the time of the BPA regulation, the agency was named Environment Canada.
7. Laura N. Vandenberg et al., Plastic Bodies in a Plastic World: Multi-Disciplinary
Approaches to Study Endocrine Disrupting Chemicals, J. CLEANER PROD. 140, 373-380 (2017).
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alternatives and work to regain the public’s trust. A robust chemicals
management strategy must provide a solid basis for assessment of
alternatives to chemicals that are identified as posing risks, such that
the replacement of those chemicals is informed and responsible,
avoiding the adoption of replacement substances that are as bad as or
worse than those replaced.8
This is a crucial moment for the science and politics of endocrine
activity and disruption. Canada, Europe, and other jurisdictions are
honing in on potential risks posed by EDCs. At the same time, many
endocrinologists and toxicologists are raising questions about the
means by which regulatory agencies evaluate the hazards and risks
posed by endocrine active substances. Scientists are making important
advances in potentially ground-breaking methodologies for the study
of endocrine disruption in particular and toxicity in general.9 In that
context, this paper aims to contribute to debates about the science, law,
and policy of endocrine disruption by articulating an interdisciplinary
research agenda which could inform not only future regulatory
decisions regarding BPA and other endocrine active substances, but
also broader political decisions about the structures and processes
through which decisions about the regulation of toxic substances are
made.
We begin with a discussion of the phenomenon of endocrine
disruption, with a focus on one of the most prominent EDCs: BPA. We
also provide a general overview of scientific approaches to identifying
EDCs (II). With this general background in place, we proceed to a
discussion of the Canadian decision to adopt regulations on the use of
BPA in infant feeding bottles and certain other products (III). We then
zoom out to provide an overview of the process for assessing risks
posed by chemicals. This discussion introduces a controversy
surrounding the testing of potential EDCs, with some scientists arguing
that conventional toxicity testing methods may not be appropriate
means for identifying EDCs. Novel approach methodologies (NAMs)
are championed by many scientists and are under examination by
regulatory agencies, but they provoke controversies of their own (IV).
We then briefly conclude (V).
8. Joel A. Tickner et al., The Nexus Between Alternatives Assessment and Green Chemistry:
Supporting the Development and Adoption of Safer Chemicals, GREEN CHEM. LETT. REV. 14, 2344 (2021); see also Joel Tickner et al., Advancing Alternatives Assessment for Safer Chemical
Substitution: A Research and Practice Agenda, INTEGR. ENVIRON. ASSESS. MANAG. 15, 855-866
(2019).
9. Daniel Krewski et al., Toxicity Testing in the 21st Century: Progress in the Past Decade
and Future Perspectives, ARCH. TOXICOL. 94, 1-58 (2020).
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ENDOCRINE DISRUPTION AND BPA

A. Endocrine Disruption
The endocrine system orchestrates the production of hormones
that are responsible for our physiological functions from conception
onwards. These hormones have essential roles in the regulation of body
functions, such as metabolism, growth and development, and sexual
function.10 They are also important for determining the development
of embryonic organs.11 Disruption of hormones can lead to altered
human development, and to many disease states such as diabetes,
infertility, or cancer.12
The potential for certain chemicals to mimic and disrupt the
normal functions of hormones was first proposed in 1958.13
Observations throughout the 1960s of strange behavioural and
reproductive patterns in animals suggested that pesticides and other
substances might be having such effects.14 In the 1970s, there was a
dramatic demonstration of the serious health hazards that endocrine
disrupting substances can cause. Diethylstilbestrol (DES), a drug with
estrogenic activity, was prescribed to women to prevent miscarriage,
treat hormone imbalance, and combat estrogen deficiency.15 DES was
subsequently linked to the development of clear-cell adenocarcinoma,
a rare type of vaginal cancer, in women whose mothers had taken the
drug during pregnancy.16
In light of these developments, in 1991 a multidisciplinary group
of experts held a conference on endocrine disruption. The Wingspread
Consensus emerged from the conference, establishing the concept of
10. ELAINE NICPON MARIEB & KATJA HOEHN, HUMAN ANATOMY & PHYSIOLOGY
(Pearson ed., 9th ed. 2013).
11. Vanessa E. Murphy et al., Endocrine Regulation of Human Fetal Growth: The Role of
the Mother, Placenta, and Fetus, ENDOCR. REV. 27,141-148 (2006).
12. MARIEB & HOEHN, supra note 11; Thaddeus T. Schug et al., Minireview: Endocrine
Disruptors: Past Lessons and Future Directions, MOL. ENDOCRINOL. 30, 833-836 (2016).
13. FX Gassner et al., Effects of Hormones on Growth, Fattening, and Meat Production
Potential of Livestock, RECENT PROG. HORM. RES. 14, 183-201 (1958).
14. Schug et al., supra note 13.
15. Mary Sue Marty et al., Endocrine Disruption: Historical Perspectives and Its Impact on
the Future of Toxicology Testing, TOXICOL. SCI. 120 Suppl 1, S93-108 (2011).
16. Id. Other impacts linked to exposure to DES include higher incidence of a number of
reproductive tract abnormalities in sons of women exposed to DES during pregnancy. WB Gill
et al., Association of Diethylstilbestrol Exposure in Utero with Cryptorchidism, Testicular
Hypoplasia and Semen Abnormalities, J. UROL. 122, 36-39 (1979).
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endocrine disruption and launching investigations into potential
endocrine-disrupting chemicals.17 In 2002, the World Health
Organization (WHO) adopted the following definition of EDCs:
an exogenous substance or mixture that alters function(s) of the
endocrine system and consequently causes adverse health effects in
an intact organism, or its progeny or (sub)populations.
A potential endocrine disruptor is an exogenous substance or
mixture that possesses properties that might be expected to lead to
endocrine disruption in an intact organism, or its progeny, or
(sub)populations.18

Given the importance of the endocrine system for human health,
exposure to EDCs during developmental periods – embryo, infant, and
adolescent – can result in long-lasting adverse health effects.19 The list
of health problems associated with exposure to EDCs has grown to
include severe reproductive and developmental problems, certain
types of cancer, diabetes, cardiovascular and thyroid disease, obesity,
and metabolic disorders.20
B. BPA
Bisphenol A (BPA) is a chemical widely used in the manufacture
of plastics. More specifically, it is found in food containers, water
bottles, children’s toys, water pipes, polycarbonate eyeglasses and
contact lenses, sports equipment, thermal paper receipts, dental
products, medical equipment, and electronics.21 It is the principal
component of epoxy resin in the linings of canned foods.22 Humans are
exposed to BPA via numerous routes, including diet, skin contact,
inhalation of household dust, and by transfer from mother to foetus
(across the placenta) or mother to baby (via lactation).23 BPA leaches
from food containers, leading to exposure as a result of the
17. THEO COLBORN & CORALIE CLEMENT, CHEMICALLY-INDUCED ALTERATIONS IN
SEXUAL AND FUNCTIONAL DEVELOPMENT: THE WILDLIFE/HUMAN CONNECTION 364
(Princeton Sci. Publ’g Co. ed. 1992).
18. World Health Organization (WHO), International Programme on Chemical Safety,
Global Assessment of the State-of-the-Science of Endocrine Disruptors (2002).
19. ANDREA C. GORE ET AL., INTRODUCTION TO ENDOCRINE DISRUPTING CHEMICALS
(EDCS) 15, (Endocrine Society ed., 2014).
20. Id.
21. Id.; Rochester, supra note 3; Laura N. Vandenberg et al., Human Exposure to Bisphenol
A (BPA), REPROD TOXICOL 24, 139-137 (2007).
22. Vandenberg et al., supra note 21.
23. Joe M. Braun et al., Impact of Early-Life Bisphenol A Exposure on Behavior and
Executive Function in Children, PEDIATRICS 128, 873-882 (2011); see also Gilbert Schönfelder et
al., Parent Bisphenol A Accumulation in the Human Maternal-Fetal-Placental Unit, ENVIRON.
HEALTH PERSPECT. 110, A703- A707 (2002).
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consumption of canned foods and beverages.24 Several environmental
and physical factors such as exposure to sunlight and microwaving food
in plastic containers enhance the transfer of BPA into the food and
beverages we consume.25 Other routes of exposure also include
inhalation of contaminated household dust, and exposure through the
skin from handling thermal paper receipts containing BPA.26 BPA and
its metabolites are found in urine27 and blood28, in umbilical cord blood
and placental tissue29, in amniotic fluid,30 in colostrum and breast
milk,31 and in the livers of foetuses.32
BPA is quickly metabolised by the body and does not accumulate
in tissues.33 Moreover, it has been shown that changes in consumption
practices, such as avoiding the use of canned foods and plastic
containers, are sufficient to decrease BPA levels in urine and other
body fluids.34 Increasing the commercial availability of BPA-free
products should reduce exposure – that is, if replacement substances
pose acceptably low levels of risk.35 However, even following Canada’s
2010 regulatory action on BPA, and the voluntary introduction into
Canadian markets of BPA-free products, data from the Report on
Human Biomonitoring of Environmental Chemicals in Canada reveal
24. Laura N. Vandenberg et al., Bisphenol-A and the Great Divide: A Review of
Controversies in the Field of Endocrine Disruption, ENDOCR. REV. 30, 75-95 (2009).
25. GORE et al., supra note 19, at 53.
26. Martin Eckardt & Thomas J. Simat, Bisphenol A and Alternatives in Thermal Paper
Receipts - A German Market Analysis from 2015 to 2017, CHEMOSPHERE 186, 1016-1025 (2017).
27. Braun et al., supra note 23.
28. Vandenberg et al., supra note 21; see also Stephanie M. Engel et al., Xenobiotic Phenols
in Early Pregnancy Amniotic Fluid, REPROD. TOXICOL. 21, 110-112 (2006).
29. Schönfelder et al., supra note 23.
30. Vandenberg et al., supra note 21.
31. Vandenberg et al., supra note 21, at 144; see also Ryoko Kuruto-Niwa et al.,
Measurement of Bisphenol A Concentrations in Human Colostrum, CHEMOSPHERE 66, 1160-1164
(2006); Yen Sun et al., Determination of Bisphenol A in Human Breast Milk by HPLC with
Column switching and Fluorescence Detection, BIOMED. CHROMATOGR. 18, 501- 507 (2004);
Xiaoyun Ye et al., Measuring Environmental Phenols and Chlorinated Organic Chemicals in
Breast Milk Using Automated On-Line Column-Switching–High Performance Liquid
Chromatography–Isotope Dilution Tandem Mass Spectrometry, J. CHROMATOGR. B 831, 110-115
(2005).
32. Muna S. Nahar et al., Fetal Liver Bisphenol A Concentrations and Biotransformation
Gene Expression Reveal Variable Exposure and Altered Capacity for Metabolism in Humans, J.
BIOCHEM. MOL. TOXICOL. 27, 116-123 (2013).
33. Jenny L. Carwile et al., Polycarbonate Bottle Use and Urinary Bisphenol A
Concentrations, ENVIRON. HEALTH PERSPECT.117, 1368- 372 (2009).
34. Camille A. Martina et al., Lifestyle Behaviors Associated with Exposures to Endocrine
Disruptors, NEUROTOXICOLOGY 33, 1427-1433 (2012); Carwile et al., supra note 33.
35. Chun Z. Yang et al., Most Plastic Products Release Estrogenic Chemicals: A Potential
Health Problem That Can Be Solved, ENVIRON. HEALTH PERSPECT. 119, 989-996 (2011).
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that BPA is still present in the environment.36 BPA thus remains a
relevant issue for the public, industry, and governments.
BPA is one of the most extensively studied EDCs. By binding to
estrogen receptors and related proteins, BPA present in the body can
potentially mimic or disrupt the functions played by estrogen.37
Because estrogen plays a pivotal role in several human organs,
including the brain, liver, bone, mammary glands, ovaries, uterus,
testes and prostate,38 disruption of estrogenic functions during
development could affect reproductive functions later in life.39 A
number of studies have associated BPA exposure with poor
reproductive health in both men and women.40 Some studies have
shown that the impact of BPA on reproductive health may be observed
in successive generations.41 Although BPA has also been associated
with other female and male fertility disorders, such as endometriosis,
miscarriage, premature birth, low birth weight, and reduced sperm
quality, more detailed clinical studies are needed to establish whether
there are causal links.42
The effects of BPA extend to a number of tissues and organs,
resulting in negative impacts on the central nervous system, the
immune system, and the pancreas.43 Potential associations between
BPA exposure and obesity have been identified.44 Epidemiological
studies tracking these conditions in human populations have also
suggested this association. Furthermore, it is thought that exposure to

36. Health Canada, Fifth Report on Human Biomonitoring of Environmental Chemicals in
Canada: Results of the Canadian Health Measures Survey Cycle 5 (2016–17) (November 2019),
https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reportspublications/environmental-contaminants/fifth-report-human-biomonitoring/page-3.html#s9-1
(last visited Aug. 17, 2020).
37. Janet C. Gould et al., Bisphenol A Interacts with the Estrogen Receptor lpha in a Distinct
Manner from Estradiol, MOL. CELL ENDOCRINOL. 142, 203-214 (1998).
38. Hye-Rim Lee et al., Functions and Physiological Roles of Two Types of Estrogen
Receptors, ER and ER , Identified by Estrogen Receptor Knockout Mouse, LAB. ANIM. RES. 28,
71-76 (2012).
39. Vandenberg et al., supra note 21.
40. Rochester, supra note 3; Vandenberg et al., supra note 21.
41. Ayelet Ziv-Gal et al., The Effects of in Utero Bisphenol A Exposure on Reproductive
Capacity in Several Generations of Mice, TOXICOL. APPL. PHARMACOL. 284, 354-362 (2015); Wei
Wang et al., In Utero Bisphenol A Exposure Disrupts Germ Cell Nest Breakdown and Reduces
Fertility with Age in the Mouse, TOXICOL. APPL. PHARMACOL. 276, 157-164 (2014).
42. Rochester, supra note 4.
43. Yelena B Wetherill et al., In Vitro Molecular Mechanisms of Bisphenol A Action,
REPROD. TOXICOL. 24, 178-198 (2007).
44. Samuel Legeay & Sébastien Faure, Is Bisphenol A an Environmental Obesogen?
FUNDAM. CLIN. PHARMACOL. 31, 594-609 (2017).
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BPA during foetal development may be the cause of the increased
prevalence of infertility, genital abnormalities, breast cancer, and
obesity, all of which are important health problems.45
Several regulatory agencies, including the World Health
Organization, Health Canada, and the United States National
Toxicology Program (NTP), have expressed concerns regarding the
potential negative impact of BPA on foetal brain development and
behaviour.46 Evidence from animal studies indicates that exposure to
BPA during development triggers anxiety, aggression, and social
interaction disorders.47 Furthermore, scientists have hypothesized that
BPA exposure may contribute to behavioural disorders such as
attention deficit hyperactivity disorder (ADHD) and autism spectrum
disorder (ASD) in children.48
C. Toxicity Testing and EDCs
Any methodology for detecting toxicity and determining the risk
of adverse health and environmental impacts as a result of exposure to
a toxic substance possesses strengths, weaknesses, limitations, and
blind spots. Furthermore, regulatory decisions on toxic substances are
inevitably made on the basis of imperfect information. Finally, those
decisions cannot, particularly in a democracy, be made on a scientific
basis alone. Regulation of a substance has ramifications that go far
beyond the economic actors with a stake in that substance, particularly
in contexts such as the current one in which little is known about the
likely replacements for regulated substances. For these and other
reasons, it is important to promote understanding of the scientific study
of EDCs and the manner in which this scientific input is incorporated
into political and legal decision-making among non-scientists,

45. Monica Muñoz-de-Toro et al., Perinatal Exposure to Bisphenol-A Alters Peripubertal
Mammary Gland Development in Mice, ENDOCRINOLOGY 146, 4138, 4144–4147 (2005); Niels E
Skakkebék et al., Germ Cell Cancer and Disorders of Spermatogenesis: An Environmental
Connection? APMIS 106, 3-11 (1998).
46. Åke Bergman et al., State of the Science of Endocrine Disrupting Chemicals 2012:
Summary for Decision-Makers, WORLD HEALTH ORG. (2013). Chloe Welch & Kimberly
Mulligan, Does Bisphenol A Confer Risk of Neurodevelopmental Disorders? What We Have
Learned from Developmental Neurotoxicity Studies in Animal Models. INT’L J. MOLECULAR SCI.
23, 2894 (2022).
47. Jennifer T. Wolstenholme et al., Gestational Exposure to Bisphenol A Produces
Transgenerational Changes in Behaviors and Gene Expression, ENDOCRINOLOGY 153, 3828-3838
(2012).
48. Marijke De Cock et al., Does Perinatal Exposure to Endocrine Disruptors Induce Autism
Spectrum and Attention Deficit Hyperactivity Disorders? Review, ACTA PAEDIATRICA101, 811818 (2012).
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including those who work in or study the law and policy of
environmental and human health protection.
Conventional methods for analysing the toxicity of substances of
concern generally involve the administration of high doses of those
substances to a small number of laboratory animals. This is a resourceintensive, time-consuming, and potentially ethically problematic
approach, which is particularly ill-suited to the evaluation of large
numbers of chemical substances for toxic properties. In addition, there
is growing evidence that chemicals that act as EDCs, such as BPA,
could have adverse health effects after exposure to low doses outside
of the range of conventional tests.49 The Canadian regulatory decision
on BPA was based on a “weight of evidence” approach in which all
available information was considered.50 Not only conventional studies
using higher doses (measured in mg/kg bodyweight/day) but also less
conventional studies, including neurobehavioral studies in which
effects were observed at low doses (measured in microgram (μg) per
kilogram of body weight per day) were taken into account.51 This
inclusive approach is of great relevance given controversies and
emerging understandings in the study of endocrine disruption.
John Peterson Myers and colleagues describe BPA as “a leading
high-profile battleground in a scientific revolution currently under way
in toxicology,”52 and argue that “[d]ata emerging from studies of
endocrine disrupting chemicals . . . challenge the central assumption
that has guided toxicology for centuries, including today’s regulatory
apparatus for assessing chemical safety.”53 In doing so, they challenge
the methods and the adequacy of chemical exposure safety standards.54
49. Sara Edge & John Eyles, Message in a Bottle: Claims Disputes and the Reconciliation of
Precaution and Weight-of-Evidence in the Regulation of Risks from Bisphenol A in Canada,
HEALTH RISK SOC. 15, 432-448 (2013)
50. Government of Canada Press Release: Government of Canada Takes Action on
Another
Chemical
of
Concern:
Bisphenol
A
(Apr.
18
2008):
https://www.canada.ca/en/news/archive/2008/04/government-canada-takes-action-anotherchemical-concern-bisphenol-a.html (last visited 31 Mar. 2022).
51. Vicente Mustieles & Mariana F Fernández. Bisphenol A Shapes Children’s Brain and
Behavior: Towards an Integrated Neurotoxicity Assessment including Human Data. ENVIRON.
HEALTH 19:66 (2020); Sarah A Johnson et al. Effects of developmental exposure to bisphenol A
on spatial navigational learning and memory in rats: A CLARITY-BPA study. HORM. & BEHAV.
80, 139–148 (2016); Shannah K Witchey et al., Perinatal bisphenol A (BPA) exposure alters brain
oxytocin receptor (OTR) expression in a sex- and region- specific manner: A CLARITY-BPA
consortium follow-up study. NEUROTOXICOLOGY 74, 139–148 (2019).
52. John Peterson Myers et al., A Clash of Old and New Scientific Concepts in Toxicity, with
Important Implications for Public Health, ENVIRON. HEALTH PERSPECT. 117, 1652-1655 (2009).
53. Id.
54. Id.
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While this view is controversial, many scientists believe that the
limitations of conventional methodologies for detecting EDCs and
informing regulatory agencies of their impacts are serious enough to
warrant heavy investment in alternative approaches and
methodologies (New Approach Methodologies or NAMs) for
toxicology testing.55 The Canadian BPA risk assessment was completed
in 2008, prior to implementation of the recommendations of the US
National Academy of Sciences report.56 Thus, the 2010 Canadian
regulation on BPA was based on data that were available prior to the
development of NAMs.
D. The Canadian Regulatory Decision on BPA
Environment Canada and Health Canada launched the Challenge
Programme in 2006, with the very ambitious goal of screening roughly
200 chemical substances that had been identified as high priorities.57
BPA was included on this list by reason of its ubiquity, which generates
a significant risk of exposure, and due to its identification in 2003 by
the European Chemicals Bureau as a potential reproductive toxicant.58
The Ministers of Health and Environment then conducted a screening
assessment, published in October 2008, involving an extensive review
of studies of BPA to determine its toxicity pursuant to the Canadian
Environmental Protection Act (CEPA).59 Exposure to BPA was
55. Stanley T Parish et al, An Evaluation Framework for New Approach Methodologies
(NAMs) for Human Health Safety Assessment, REGUL. TOXICOL. PHARMACOL. 112, 104592
(2020).
56. Melvin E Andersen & Daniel Krewski, Toxicity Testing in the 21st Century: Bringing the
Vision to Life, TOXICOL. SCI. 107, 324-330 (2008).
57. “Challenge” for Chemical Substances That Are a High Priority for Action, GOV’T OF
CANADA, (July 28,
2011),
https://www.canada.ca/en/health-canada/services/chemicalsubstances/challenge.html, (last visited Mar. 31, 2022). The Ministers of Environment and Health
are required by s. 73 of CEPA to prepare lists of priority substances for screening on the basis
either of high levels of exposure or persistence, bioaccumulation, or toxicity. For an analysis of
the debates over BPA among scientists, regulators, and a range of stakeholders, see Sara Edge &
John Eyles, supra note 50; Steve Maguire & Cynthia Hardy, Organizing Processes and the
Construction of Risk: A Discursive Approach, 56 ACAD. MANAG. J. 231 (2013).
58. Environment Canada Health Canada, Screening Assessment for the Challenge: Phenol,
4,4’ -(1-Methylethylidene)Bis- (Bisphenol A), (Oct. 2008), https://www.ec.gc.ca/ese-ees/3C756383BEB3-45D5-B8D3-E8C800F35243/batch2_80-05-7_en.pdf., (last visited Apr. 20, 2022); Updated
European
Union
Risk
Assessment
Report
4,4’-ISOPROPYLIDENEDIPHENOL
(BISPHENOL-A),
EUROPEAN
UNION
(2008),
https://publications.jrc.ec.europa.eu/repository/handle/JRC59988, (last visited Apr. 20, 2022).
59. CEPA provides that a substance is to be considered toxic “if it is entering or may enter
the environment in a quantity or concentration or under conditions that
have or may have an immediate or long-term harmful effect on the environment or its biological
diversity;
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widespread due to the high volume of its use in Canada; slow
degradation in oxygen-poor environments; its detection in various
environmental media; and high bioavailability (that is, the capacity of
the chemical to enter the organism and reach its site of action).60 In
addition to exposure data, evidence of adverse health outcomes was
considered:
Low-level exposure to bisphenol A, particularly at sensitive life cycle
stages, may lead to permanent alterations in hormonal,
developmental or reproductive capacity. In laboratory testing, these
effects have occurred within the range of concentrations measured
in Canada, indicating that there is potential for adverse effects in
populations, particularly close to point sources.61

This evidence, the report states, is “highly uncertain” but “suggestive
of potential effects” at doses that correspond to human exposure levels,
mainly through diet.62 When combined with the knowledge that BPA
leaches out of plastic bottles into the contents,63 and evidence of a
correlation between prenatal and neonatal exposure to BPA and
reproductive and developmental problems,64 the agencies determined
that a case for regulatory action could be made on a precautionary
basis.65 The screening assessment report notes inconsistent results
across different studies,66 and, as indicated above, there is still
controversy in scientific and regulatory communities regarding the
health impacts of BPA.67
On the basis of the BPA screening assessment report, this

constitute or may constitute a danger to the environment on which life depends; or
constitute or may constitute a danger in Canada to human life or health:” Canadian
Environmental Protection Act, S.C. 1999, c.33, §64 (Can.).
The Ministers of Health and Environment are charged with conducting screenings for toxicity in
virtue of CEPA. Id. at § 74.
60. Tyler Pollock et al., Trends in Environmental Chemical Concentrations in the Canadian
Population: Biomonitoring Data from the Canadian Health Measures Survey 2007-2017.
ENVIRON. INT. 155, 106678 (2021).
61. Environment Canada Health Canada, supra note 59.
62. Id.
63. Id.
64. Reproductive and developmental problems are not the only health impacts discussed in
the report; they receive attention here because of their salience to the Canadian regulatory
response.
65. CEPA, supra note 60, § 76.1.
66. Environment Canada Health Canada, supra note 59.
67. Jerrold J. Heindel et al., Data Integration, Analysis, and Interpretation of Eight Academic
CLARITY-BPA Studies, REPROD. TOXICOL. 98, 29-60 (2020); L. Camacho et al., A Two-year
Toxicology Study of Bisphenol A (BPA) in Sprague-Dawley Rats: CLARITY-BPA Core Study
Results, FOOD CHEM. TOXICOL. 132, 110728 (2019).
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substance was added to the List of Toxic Substances.68 The next step
was to develop a risk management approach.69 The objective identified
was to minimise infant exposure “to the greatest extent practicable,”70
more specifically “to achieve the lowest level of release to infant
formula and from polycarbonate baby bottles that was technically and
economically feasible.”71 In 2010, after a 60-day consultation period for
the proposed risk management plan,72 the regulations of the Hazardous
Products Act73 were amended to ban BPA in baby bottles. By the time
the regulation entered into force, BPA was no longer found in baby
bottles. Manufacturers, retailers, and consumers had by then moved to
alternatives, which included bottles with plastic linings, glass or metal
bottles, and plastic bottles that were BPA-free – and clearly labelled as
such, as otherwise they would not sell.74
E. The Screening Assessment Report
The BPA screening assessment report is a review of a large
number of scientific studies on BPA’s chemical properties, the uses to
which BPA is put, exposure of members of the population to BPA, and
the hazards BPA presents.75 It is an ambitious review of BPA studies
following a range of methodologies and approaches. As will be
discussed in further detail below, scientific studies of adverse health
effects proceed in different ways depending on the particular research
questions on which scientists wish to focus. For example, laboratory

68. CEPA, supra note 60, § 90; Order Adding a Toxic Substance to Schedule 1 to the
Canadian Environmental Protection Act, S.C. 2021. SOR/2021-86 (Apr. 23, 2021)
https://canadagazette.gc.ca/rp-pr/p2/2021/2021-05-12/html/sor-dors86-eng.html, (last visited Apr.
20, 2022).
69. Environment Canada Health Canada, Proposed Risk Management Approach for
Phenol, 4,4’-(1-Methylethylidene) Bis (Bisphenol A), GOV’T OF CANADA, 1, 4 (Oct. 2008)
https://www.ec.gc.ca/ese-ees/6FA54372-A09E-45CD-8A5F-39EBDD55D13A/batch2_80-057_rm_en.pdf, (last visited Apr. 20. 2022).
70. Id. at 12.
71. Id. at 13.
72. Id at 16. Consolidated comments from that process are presented in Summary of Public
Comments Received on the Government of Canada’s Proposed Risk Management Approach
Document on Phenol, 4,4’ -(1-Methylethylidene)Bis- (CAS RN 80-05-7), GOV’T OF CANADA,
(Oct.
2010)
https://www.ec.gc.ca/ese-ees/FFCB9B55-44CA-40F5-A53F355FB1769546/batch2_80-05-7_rm_pc_EN.pdf, (last visited Apr. 20, 2022). Not surprisingly,
comments ranged from complaints that the government had gone too far on a flimsy scientific
basis to complaints that it had not gone far enough by not slating BPA for elimination. Id.
73. Hazardous Products Act; Hazardous Products Regulation; Order Amending Schedule I
to the Hazardous Products Act (bisphenol A) 2010 (Canada Gazette, Part II).
74. Maguire & Hardy, supra note 58.
75. Environment Canada Health Canada, supra note 59.
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studies often involve the exposure of a relatively small number of
animals, generally rodents, to high levels of the chemical of interest
over a fixed period of time. In contrast, large human populations may
be exposed to lower levels of the chemical of interest for a longer time.
Such cases present a natural experiment that epidemiologists can
analyse to learn more about the impacts of chemicals on humans. For
example, a population may be exposed to a large amount of a substance
over a short period of time (acute exposure) as a result of a major
chemical leak. Epidemiological methods may also be employed when
a group of employees in a factory are exposed to small amounts of a
substance over the course of their professional lives (chronic
exposure). Epidemiologists also examine associations between
everyday exposures to a wide array of chemicals and health outcomes.
As a general rule, epidemiological studies provide evidence of
association between an exposure and an effect but can rarely be used
for establishing causality. Laboratory studies typically focus on a
relatively narrow range of some of the more serious health risks,
namely organ toxicity, carcinogenicity, mutagenicity, immunotoxicity,
and reproductive and developmental toxicity. Such studies can use a
relatively small number of animals because laboratory animals have
highly controlled genetic and environmental conditions. This means a
single variable can be tested, i.e., exposure to a specific chemical.
Exposures may be acute (single dose or over a short time) or chronic
(repeated doses over a longer time). If scientists are interested in
honing in on the impacts of a chemical on a particular organ, function,
or process, it may be feasible to use in vitro laboratory techniques in
which cells or organs are cultured and then exposed to a substance or
mixture. This is a very short list of the myriad approaches that scientists
may take to study various dimensions of a substance’s toxicity. Each
presents its own strengths, weaknesses, and limitations. Scientists and
regulatory authorities are able, by looking at large numbers of studies
carried out using a variety of approaches and methods, to develop a
more complete picture of the risks posed by exposure to substances
such as BPA.
The approach taken in the screening assessment report prepared
by Environment and Health Canada was to look at a wide range of
scientific studies and data on BPA. The report’s authors used a
weighted approach,76 meaning that they did not treat all studies and
data as equally worthy of confidence and therefore equally reliable. A

76. Environment Canada Health Canada, supra note 59, at 2.
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study whose results generate a lower level of confidence may
nevertheless provide valuable information and insight and therefore be
worth taking into consideration, even if there are good reasons not to
depend heavily on its results. For example, it may involve only a small
sample or use novel methodologies or experimental designs. A
weighted approach allows assessors to consider a broad and deep body
of evidence while at the same time taking account of the different
degrees of confidence that various studies generate.
Weighted reviews of a wide range of scientific literature and other
data constitute a well-accepted approach to informing regulatory
decisions regarding toxic substances, but they are not without
controversy. Regulatory authorities seek to ensure that the procedures
followed for generating the scientific data that inform regulatory
decisions are described carefully and adhered to scrupulously in order
to promote transparency, consistency, rigour, and objectivity. It is
widely acknowledged that weighting scientific evidence for
consideration in a risk assessment depends on professional judgment;
this means that, quite inevitably, different professionals may not reach
precisely the same conclusion. However, the exercise of this discretion
need not be arbitrary or subjective if a robust methodology is adopted
for weighting studies and other pieces of evidence, along with
transparency regarding that methodology and the manner in which it
was applied.77
F. Regulatory Responses by other Jurisdictions
The varied responses of different jurisdictions78 to the evolving
77. The research teams responsible for two consecutive reports on EDCs prepared for the
World Health Organization and the United Nations Environment Program traded criticisms of
one another’s methodologies following the publication of the second of these reports. James C.
Lamb IV et al., Critical Comments on the WHO-UNEP State of the Science of Endocrine
Disrupting Chemicals–2012, REGUL. TOXICOL. PHARM. 69, 22-40 (2014); Åke Bergman et al.,
Manufacturing Doubt about Endocrine Disrupter Science–A Rebuttal of Industry-Sponsored
Critical Comments on the UNEP/WHO Report “State of the Science of Endocrine Disrupting
Chemicals 2012, REGUL. TOXICOL. PHARMACOL. 73, 1007-1017 (2015) (comparing International
Programme on Chemical Safety, Global Assessment of the State-of-the-Science of Endocrine
Disruptors, WHO (2002) https://www.who.int/ipcs/publications/en/toc.pdf?ua=1; A. Bergman et
al., State of the Science of Endocrine Disrupting Chemicals, WHO (2012)
https://apps.who.int/iris/bitstream/handle/10665/78102/WHO_HSE_PHE_IHE_2013.1_eng.pdf,
(last visited Apr. 20, 2022).
78. As noted above, Canada’s ban was prompted in part by risk assessments in Europe.
Following Canada’s regulatory action, the European Union banned BPA in baby bottles in 2011.
Commission Directive 2011/8/EU, OFF. J. EUR. UNION (Jan. 28, 2011) (regarding the restriction
of use of Bisphenol A in plastic infant feeding bottles 2011). For an overview and analysis of
earlier European initiatives on BPA, see Tessa Fox et al., Regulating the Use of Bisphenol A in
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scientific understanding of BPA and other bisphenols indicate that
regulatory authorities are unclear on how to react to these emerging
scientific insights. Varied responses across jurisdictions may be due to
timing with respect to the information available at the time of the
assessment (2008 versus 2017) or legislative differences between
jurisdictions such as Canada and Europe. In Canada, under CEPA, risk
is assessed on the basis of exposure and hazard, whereas in Europe,
evaluation of risks posed by EDCs is largely based on hazard.79
Companies whose products are traded internationally may need to
comply with more stringent requirements than those imposed in their
own jurisdictions. The actions taken by Canada in 2010 may appear
modest now, a decade later, but at the time were a world first.
Regarding the modesty of the Canadian measures, one interesting
observation is that manufacturers of infant formula have not waited for
Canadian regulators to address that issue. There is some indication that
the Canadian regulation is being treated by many constituencies as a
floor rather than a ceiling, and manufacturers are responding to
scientific insights and consumer concerns rather than waiting for
Baby and Children’s Products in the European Union: Current Developments and Scenarios for
the Regulatory Future, EUR. J. RISK REGUL. 2, 21-35 (2011). Denmark, Belgium, and Sweden
have taken additional actions against BPA in food contact materials intended for infants and
young children; and France has banned the substance in all food contact materials. European
Parliamentary Research Service, New Rules on Bisphenol A in Food Contact Materials, EUR.
PARLIAMENT,
(Feb.
2018)
https://www.europarl.europa.eu/RegData/etudes/ATAG/2018/614705/EPRS_ATA(2018)614705
_EN.pdf, (last visited Apr. 20, 2022). Among some of the other steps taken by European agencies,
four are worthy of particular note: the decision by the Member State Committee of the European
Chemicals Agency (ECHA) to identify BPA as a Substance of Very High Concern (SVHC),
European Chemicals Agency, Agreement of the Member State Committee on the Identification of
4,4’-Isopropylidenediphenol (Bisphenol A) as a Substance of Very High Concern (Dec. 14, 2017)
https://echa.europa.eu/documents/10162/81862f4e-92bc-6f64-9a01-42565b526022, (last visited
Apr. 20, 2022); the extension by the European Parliament of the BPA ban to all food contact
materials intended for infants and young children, Commission Regulation EU 2018/213, OFF. J.
EUR.
UNION
(Feb.
12,
2018)
https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32018R0213&from=EL, (last visited Apr. 20, 2022)
(regarding the use of that substance in Plastic Food Contact Materials 2018); the European
Commission decision to ban BPA in thermal paper, such as that used in receipts, Commission
Regulation EU 2016/2235, OFF. J. EUR. UNION (Dec. 12, 2016) https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32016R2235&from=EN, (last visited Apr. 20, 2022)
(introduced in 2016, the ban will take effect in 2020); and the most recent action, a resolution of
the European Parliament calling on the European Commission to take further steps to regulate
endocrine disrupting substances, treating them in a similar manner to substances with
carcinogenic or mutagenic substances, or substances that are toxic for reproduction, Resolution
on a Comprehensive European Union Framework on Endocrine Disruptors, EUR. PARL. DOC.
P8_TA-PROV(2019) 0441.
79. Christopher D Kassotis et al., Endocrine-Disrupting Chemicals: Economic, Regulatory,
and Policy Implications, LANCET DIABETES ENDOCRINOL. 8, 719-730 (2020).
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regulatory agencies to impose further restrictions on this substance.
This desire to get ahead of the regulatory curve is not particularly
surprising. Manufacturers and retailers are reacting not only to
scientific insights into bisphenols, but also to public discomfort with
those substances and, in some cases at least, the availability of
alternatives that may permit the avoidance of bisphenols altogether.
The fact that bisphenols are receiving increased scrutiny by scientists
and regulators creates incentives to look elsewhere when designing
products.
The screening assessment report was prepared, and the regulatory
decision taken, against a backdrop of uncertainty and controversy.
There were also rapid developments in scientific approaches to
studying toxicity that many commentators have argued presage a
paradigm shift.80 These developments have important implications for
regulatory agencies, and therefore stakeholders. In what follows, this
broader context will be further explored to shed additional light on the
Canadian regulatory decision on BPA, on the process leading up to it,
and on emerging approaches and methodologies that promise to put
additional tools at the disposal of agencies responsible for the
regulation of toxic substances.
III.

THE RISK ASSESSMENT PROCESS

Toxicity testing methodologies have been developed and refined
over the course of decades, and there is a high degree of consensus
among scientists and regulators as to their appropriateness and
reliability. However, this consensus is beginning to break down as far
as EDCs are concerned. Even among observers who maintain a high
degree of confidence in conventional methodologies, there are
concerns about the time and resources they require, as well as the
ethical problems that the use of laboratory animals poses.
A. Clarity
As noted above, the endocrine disrupting potential of BPA is an
extremely well-studied phenomenon – yet it also remains highly
controversial. In an attempt to address knowledge gaps, uncertainties,
and disagreement among scientists, the Consortium Linking Academic
and Regulatory Insights on Bisphenol A Toxicity (CLARITY-BPA)
was created in the United States by the National Institute of

80. Hongmao Sun et al., Paradigm Shift in Toxicity Testing and Modelling, AAPS J 14, 473480 (2012).
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Environmental Health Sciences (NIEHS) and the National Center for
Toxicological Research (NCTR) of the Food and Drug Administration
(FDA).81 CLARITY involved a further round of studies on BPA that
were designed to generate consensus regarding its status as an EDC.82
Key to attaining this objective was the assembly of scientists from
regulatory agencies, academia, and industry. This was in
acknowledgement of the fact that scientific studies tend to be
structured differently depending on their aims, which in turn are
influenced by the intended audience: academia, regulatory agency, or
industry. Many of the BPA studies in which endocrine disruption has
been observed were academic studies, seeking to expand the
boundaries of knowledge and often employing novel methodologies.
These studies were often not conducted using the standardised
experimental protocols referred to as good laboratory practices (GLP).
83
Regulatory agencies have generally placed a great deal of emphasis
on strict adherence to GLP standards, in order to generate a high
degree of reproducibility and thus to promote consistency and evenhandedness.84 The CLARITY-BPA study sought “to bridge guidelinecompliant research conducted at the FDA,” that is, in conformity with
such standardised protocols, “with hypothesis-based research
investigations conducted by academia on the toxicity of BPA.”85 The
aim was to reduce differences between studies and to understand the
full range of potential adverse health effects from exposure to BPA.86
However, due to the differences in the parameters that were measured
(i.e., standard study designs and endpoints assessed under GLP
guidelines for regulatory purposes in industry or government labs
versus specific, more focussed study designs and measures (not GLP)
in academic research laboratories), CLARITY did not resolve the

81. Thaddeus T Schug et al. A New Approach to Synergize Academic and Guidelinecompliant Research: The CLARITY-BPA Research Program. REPROD TOXICOL 40, 35-40 (2013);
Heindel et al., supra note 68.
82. L. Camacho et al., supra note 68.
83. John Peterson Myers et al., Why Public Health Agencies Cannot Depend on Good
Laboratory Practices as a Criterion for Selecting Data: The Case of Bisphenol A, ENVIRON.
HEALTH PERSPSECT . 117, 309-315 (2009).
84. See Id. at 309–10 (noting why regulatory agencies established GLP).
85. NAT’L TOXICOLOGY PROGRAM U.S. DEP’T OF HEALTH AND HUMAN SERV., NTP
RESEARCH REPORT ON THE CLARITY-BPA CORE STUDY: A PERINATAL AND CHRONIC
EXTENDED-DOSE- RANGE STUDY OF BISPHENOL A IN RATS, ii (2018).
86. Gail S. Prins et al., CLARITY BPA Academic Laboratory Studies Identify Consistent
Low dose Bisphenol A Effects on Multiple Organ Systems, BASIC CLIN PHARMACOL. TOXICOL.
125, 14-31 (2019).
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controversies. In fact, it added to them.87 An important dimension of
this controversy turns on the issue of effects at different doses: the
presumption that effects will increase in frequency and severity at
higher doses is central to conventional approaches to toxicology, and
was an important point of contention between scientists conducting
GLP studies and those using alternative or novel methods.88 To better
understand this controversy and the uncertainty that it generates for
regulatory agencies and stakeholders, we take a closer look at the
evaluation of risks posed by toxic substances.
B. Exposure and Hazard
While it can seem counterintuitive for a regulatory agency not to
proceed with prohibitions or strict regulation of a substance as soon as
it has been classified as toxic, it is crucial to bear in mind that hazard is
only one element of risk. The other element is exposure. This is
exemplified by the epidemiological and toxicological mantra that “the
dose makes the poison:” many substances that have a neutral or
positive impact on human health and well-being at certain levels of
exposure become problematic only once exposure begins to reach
higher levels.89 It is when individuals in a population are exposed to a
substance of concern at a level that is correlated with a negative impact
on health outcomes that they are deemed to be at risk. The terms risk
and hazard are distinct for the purposes of toxicology.90 Risk refers to
the probability of harm based on both hazard and exposure, and exists
only in situations where exposure to the hazardous chemical has
occurred, or will occur, at levels that cause harm.91
The level, frequency, route, and duration of exposure to a
chemical (exposure assessment) and the relationship between dose and
effect (dose-response relationship) are evaluated in the risk assessment
process.92 Chemical risk assessments are based on a very large number
87. Patricia A. Hunt et al., The Bisphenol A Experience: A Primer for the Analysis of
Environmental Effects on Mammalian Reproduction, BIOL. REPROD. 81, 807-813 (2009).
88. L. Camacho et al., supra note 68; Heindel et al., supra note 68 (describing how several
independent lab studies observed non-linear dose-response functions).
89. Die dritte Defension wegen des Schreibens der neuen Rezepte, SEPTEM
DEFENSIONES 1538. Werke Bd. 2, Darmstadt 1965, 510.
90. National Research Council (US) Committee on the Institutional Means for Assessment
of Risks to Public Health. Risk Assessment in the Federal Government: Managing the Process.
Washington (DC): National Academies Press (US); 1983. PMID: 25032414.
91. C.J. VAN. LEEUWEN & T.G. VERMEIRE, RISK ASSESSMENT OF CHEMICALS: AN
INTRODUCTION (2nd ed. 2007).
92. Maged Younes, Toxicological Risk Assessment, in REGUL. TOXICOL. PHARM. 65, 67
(Franz-Xaver Reichl & Michael Schwenk eds.) (2014); CURTIS D. KLAASSEN & JOHN B.
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of scientific studies that are carried out using methodologies and
protocols that have been developed over the course of decades,
subjected to rigorous validation, and, in many cases, approved by
domestic regulatory agencies and international organisations such as
the Organization for Economic Cooperation and Development
(OECD).93 Reliance on the use of these well-described, validated
guideline protocols to evaluate the adverse health effects of chemicals
provides assurance to international regulatory agencies, governments,
and stakeholders that conclusions are based on sound data.
Furthermore, the basis on which decisions are made can be explained
to a broad audience, including manufacturers and consumers, and
assurance is provided that all chemical risks are handled in the same
manner, reducing disparities, arbitrariness, and subjective risk
assessments.
Consideration of the interrelationship between hazard and
exposure, which together permit an assessment of risk, sheds light on
the Canadian government’s decision to regulate BPA in baby bottles
and similar items, but not to go further. It is important to acknowledge
the hybrid nature of the category of “CEPA toxicity”, that is, meeting
the criteria in CEPA for listing as a toxic substance. Heavily informed
by science, the concept encompasses more considerations than the
inherent qualities of the substance itself.94 The hybrid nature of the
concept of CEPA toxicity is also made clear from the role played by
precaution in the decision-making process. The health risks posed by
BPA were not deemed to have been conclusively established by the
data generated in toxicity tests, but a potential risk was nevertheless
identified on a precautionary basis.95 Recall as well that the issue of
exposure loomed large: BPA is ubiquitous in our environment;
Canadians (and people in the developed world in particular) are
exposed to the substance through contact with a wide variety of
products and pathways; and the substance is found, albeit at low
concentrations, in a number of human body fluids and tissues. While it
is eliminated from the body very quickly, its endocrine disrupting
properties may make humans particularly vulnerable to its effects at
certain developmental stages, including in utero, infancy, and puberty.
WATKINS III, CASARETT & DOULL’S ESSENTIALS OF TOXICOLOGY (Third ed., McGraw-Hill
Medical 2015).
93. Daniel Krewski et al., Toxicity Testing in the 21st Century: A Vision and a Strategy, J.
TOXICOL. ENVIRON. HEALTH B CRIT. REV., 13, 51–138 (2010).
94. Canadian Environmental Protection Act, S.C. 1999, c.33, §64 (Can.).
95. BUREAU OF CHEM. SAFETY, HEALTH RISK ASSESSMENT OF BISPHENOL A FROM FOOD
PACKAGING APPLICATIONS, 10 (2008) (Can.).
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As a result, a conclusion was reached that for most Canadians in most
circumstances, the potential risk was acceptable.
BPA has received an enormous amount of attention from
scientists, yet its health risks remain only partially understood. Part of
the reason for this incomplete information and uncertainty may lie with
certain characteristics of endocrine disrupting substances, namely their
capacity to induce changes (not necessarily harmful ones) at low doses.
As noted, many experts question whether conventional toxicity testing
using high doses is appropriate for suspected EDCs. Since hormones
play a critical role in maintaining homeostasis throughout the body, the
small changes in hormones that result from exposure to an EDC may
have long-lasting and significant effects, especially at sensitive life
stages.
C. Dose-Response Relationships
One of the major challenges faced by scientists in regulatory
agencies, government, industry, and academic labs is to understand the
relationship between an exposure, or dose, and an adverse health
effect, or toxicity. In a conventional toxicology approach, it is predicted
that increasing the dose will increase the response, rendering adverse
outcomes more frequent or more severe.96 This type of dose-response
relationship is termed monotonic.97 In the design of such an
experiment, a group of animals serves as the control, not being exposed
to the chemical under investigation. Other groups are treated with
different doses of the chemical of interest. The lowest dose at which
there is no response is identified as the No Observed Adverse Effect
Level (NOAEL).98 The lowest dose which produces a response is
identified as the Lowest Observed Adverse Effect Level (LOAEL).99
The LOAEL serves as the “point of departure” to be used as a basis
for making the extrapolations needed for assessing risks.100
Information garnered from experimental results will often be

96. Michael A. Dorato & Jeffery A. Engelhardt, The No-Observed-Adverse-Effect-Level in
Drug Safety Evaluations: Use, Issues, and Definition(s), REGUL. TOXICOL. PHARM. 42, 265-274
(2005).
97. Rory B. Connolly & Werner K. Lutz, Nonmonotonic Dose-Response Relationships:
Mechanistic Basis, Kinetic Modeling, and Implications for Risk Assessment, TOXICOL. SCI. 77, 151157 (2004).
98. Dorato & Engelhardt, supra note 96.
99. Laura N. Vandenberg, Low-Dose Effects of Hormones and Endocrine Disruptors,
VITAM. HORM. 94, 129-165 (2014).
100. Hoda Izadi et al., Evaluation of a Benchmark Dose for Point of Departure Determination
for a Variety of Chemical Classes in Applied Regulatory Settings, RISK ANAL. 32, 830-835 (1998).
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supplemented through mathematical modelling: for example, scientists
may use experimental results to calculate the dose associated with a
specific change, perhaps a 10% increase in the incidence of an adverse
effect, as compared to control. This dose is then defined as the
benchmark dose for this chemical and endpoint.101
Once the NOAEL, LOAEL and/or the benchmark dose for a
response are determined in a toxicology study, risk assessors may apply
uncertainty factors to adjust for knowledge gaps associated with these
data. Uncertainty factors are used to address the extrapolation of data
from animal studies to effects on humans; for different impacts within
individuals in a population; and for differences in doses in laboratory
experiments as opposed to real-world exposures, among other
things.102 Chemicals may affect pathways or targets in animals but not
humans, or be handled differently in animals and humans. Human
responses may vary since individuals are unique.103 It may be difficult
to extrapolate from a short-duration animal study to a lifetime of
human exposure. There is uncertainty in estimating a no-effect level
from a dose where effects are observed. Finally, the most subtle
adverse effect may not have been evaluated. Uncertainty factors are
applied to account for these knowledge gaps and sources of
variability.104
One of the important questions in toxicology is whether chemicals
have toxic effects only when the exposure is above a certain level or
threshold. The threshold is defined as the dose below which no adverse
effects are observed after exposure to a chemical.105 The failure to
observe effects could result from different factors. Perhaps exposure to
only a few molecules is not sufficient to produce significant changes in

101. Miwako Dakeishi et al., Relation between Benchmark Dose and No observed adverse
effect Level in Clinical Research: Effects of Daily Alcohol Intake on Blood Pressure in Japanese
Salesmen, RISK ANAL. 26, 115-123 (2006).
102. Peter M. Chapman et al., A Critical Evaluation of Safety (Uncertainty) Factors for
Ecological Risk Assessment, ENVIRON. TOXICOL. CHEM. 17, 99-108 (2009).
103. HEALTH CANADA, SCIENCE POLICY NOTE: THE APPLICATION OF UNCERTAINTY
FACTORS AND THE PEST CONTROL PRODUCTS ACT FACTOR IN THE HUMAN HEALTH RISK
ASSESSMENT OF PESTICIDES 6 (2008) (Can.).
104. Health Canada describes the use of uncertainty factors as follows:
The term “uncertainty factor” is used to denote factors associated with interspecies
extrapolation, intraspecies variation, extrapolation from a LOAEL to a NOAEL where
no NOAEL is available, extrapolation for duration of dosing and database deficiencies.
HEALTH CANADA, SCIENCE POLICY NOTE: THE APPLICATION OF UNCERTAINTY
FACTORS AND THE PEST CONTROL PRODUCTS ACT FACTOR IN THE HUMAN HEALTH
RISK ASSESSMENT OF PESTICIDES 5 (2008) (Can.).
105. Conducting a Human Health Risk Assessment, U.S. ENV’T PROT. AGENCY,
https://www.epa.gov/risk/conducting-human-health-risk-assessment (last visited Jan. 27, 2022).
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an organism, which might mean that the organism is able to repair any
damage that might be caused. However, it might also mean that no
effects are observed because the numbers of animals tested were too
low to determine, with confidence, the effects of exposure at a low
dose. Toxicologists have generally accepted that there is no threshold
for chemicals that act as mutagens, by damaging DNA or changing the
DNA reading sequence. In other words, it is assumed that any level of
exposure to these chemicals may cause harm. Ingredients in cigarette
smoke serve as an example. Many of the chemicals found in cigarette
smoke do cause DNA damage; human epidemiology studies have
associated even passive smoking (exposure to second-hand smoke)
with adverse health effects.106 Based on this evidence, many scientists
and regulatory agencies conclude that there is no safe level of exposure
to these chemicals—in other words, no threshold. This has led many
jurisdictions to seek to reduce exposure as much as possible, for
example by banning smoking cigarettes indoors, in cars, and near
building entrances.
The question that many scientists and regulatory authorities are
facing is how to assess the risk associated with exposure to chemicals
for which the relationship between dose and health effects is not
monotonic—that is, does not follow the pattern whereby a greater dose
leads to a greater effect. Some studies of EDCs, including a number
with BPA, have reported effects at low doses that were not observed
at higher doses.107 This phenomenon is known as a non-monotonic
dose-response relationship (NMDR).108 A review of the scientific
literature on BPA reveals that the detection of NMDRs varies
according to both the endpoints being measured and the number of
doses evaluated in individual studies. There is an increase in the
detection of NMDRs in studies with higher numbers of doses.109
NMDRs may be U-shaped, meaning that the highest response for the
endpoint that is measured occurs in the lowest and highest dose ranges,
or have an inverted U-shape, in which the highest response occurs in

106. NATIONAL RESEARCH COUNCIL, ENVIRONMENTAL TOBACCO SMOKE: MEASURING
EXPOSURES AND ASSESSING HEALTH EFFECTS 8–12 (1986).
107. Laura N Vandenberg et al., Hormones and Endocrine-Disrupting Chemicals: Low-Dose
Effects and Nonmonotonic Dose Responses, ENDOCR. REV. 33, 378-455 (2012); Fabien Lagarde
et al., Non-Monotonic Dose-Response Relationships and Endocrine Disruptors: A Qualitative
Method of Assessment ENVIRON. HEALTH 14, 13 (2015).
108. Lagarde et al., supra note 74.
109. Corinne E Hill et al., Nonmonotonic Dose–Response Curves occur in Dose Ranges that
are Relevant to Regulatory Decision-Making, DOSE-RESPONSE 16, 1559325818798282 (2018).
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the intermediate dose range.110
Health effects at low, environmentally relevant doses111 have been
observed in human population studies.112 Human epidemiological
studies may follow a cohort, or a large group of subjects, for many
years, or they may be based on natural experiments such as chemical
spills or workplace exposure to a substance that is later identified as
toxic. There are concerns that these effects may not be observed in the
conventional toxicology testing used to inform regulatory decisions
and may therefore be excluded from the risk assessment process.
However, the data from epidemiological experiments are often
available only after the fact, once a chemical is found in the
environment at levels that have raised concern, which means that these
insights are too sporadic and arrive too late to play a role in preventing
exposures that may be associated with adverse health effects.
Concern about the ability of toxicity tests to detect NMDRs
associated with low-dose effects and exposure to some EDCs, such as
BPA, led the United States Environmental Protection Agency (EPA)
to ask the National Academies of Sciences, Engineering, and Medicine
to form a committee to develop a strategy to evaluate the evidence for
endocrine-related low-dose effects.113 Based on a review of both animal
and human studies for two EDCs, phthalate plasticisers and
brominated flame retardants, the Committee observed that there were
similar outcomes in animals and humans and that even though dose
ranges differed, the magnitude of changes (effect estimates) were
similar.114 The integration of these approaches can increase confidence
in the data.
IV.

INTRODUCTION OF NEW APPROACHES TO TOXICITY
TESTING

In a ground-breaking report entitled Toxicity Testing in the 21st

110. Vandenberg supra note 70, at 138.
111. An environmentally relevant dose is a dose that is or could be observed in real-world
conditions.
112. Andrea C. Gore et al., Implications of Prenatal Steroid Perturbations for
Neurodevelopment, Behavior, and Autism, ENDOCR. REV. 35, 961-991 (2014); Åke Bergman et
al., The Impact of Endocrine Disruption: A Consensus Statement on the State of the Science,
ENVIRON. HEALTH PERSPECT. 121, A104-106 (2013); Vandenberg supra note 74.
113. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE, APPLICATION
OF SYSTEMATIC REVIEW METHODS IN AN OVERALL STRATEGY FOR EVALUATING LOW-DOSE
TOXICITY FROM ENDOCRINE ACTIVE CHEMICALS 1 (2017).
114. NATIONAL ACADEMIES OF SCIENCE, ENGINEERING, AND MEDICINE, supra note 115,
at 159.
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Century: A Vision and Strategy, published in 2007, the United States
National Research Council (NRC) referred to “a revolution” in
biology building on
progress being made in the elucidation of cellular-response
networks. Those networks are interconnected pathways composed
of complex biochemical interactions of genes, proteins, and small
molecules that maintain normal cellular function, control
communication between cells, and allow cells to adapt to changes in
their environment.115

The Toxicity Testing in the 21st Century report (TT21C) was born of
an initiative by the EPA and the US National Institute of
Environmental Health Sciences (NIEHS) to develop guidance for new
approaches to toxicity testing.116 The NRC’s objectives for such new
approaches were identified as follows:
•
•
•
•

Provide broader coverage of chemicals and their mixtures,
end points, and life-stage vulnerabilities.
Reduce the cost and time of testing, increase efficiency and
flexibility, and make it possible to reach a decision more
quickly.
Use fewer animals and cause minimal suffering to animals
that are used.
Develop a more robust scientific basis of risk assessment by
providing detailed mechanistic and dosimetry information
and by encouraging the integration of toxicologic and
population-based data.117

One of the problems identified by the NRC consisted of “major gaps
in current toxicity-testing approaches,” while emerging technologies
are deemed to hold “great promise for screening chemicals more
rapidly.”118 In addition to considerations arising from the drive to
refine, reduce and replace animal use (3Rs),119 the NRC noted that “the
relevance of . . . animal studies [involving high doses] for the
assessment of risks to heterogeneous human populations exposed at
much lower concentrations has been questioned.”120
The TT21C report proposes “a transformative paradigm shift”
involving in vitro (cell or organ cultures, lower species animal models,
115. NATIONAL RESEARCH COUNCIL (NRC), Toxicity Testing in the 21st Century: A Vision
and a Strategy 36 (2007).
116. Id. at 1–2.
117. Id. at 42–3.
118. Id. at 28.
119. W.M.S. Russell and R.L. Burch, The Removal of Inhumanity: The Three R’s, THE
PRINCIPLES OF HUMANE EXPERIMENTAL TECHNIQUE (spec. l ed., Universities Federation for
Animal Welfare 1992) https://caat.jhsph.edu/principles/chap4d.
120. NATIONAL RESEARCH COUNCIL, supra note 116 at 35.
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or in silico computer modelling) methodologies to predict toxicity,
rather than relying on in vivo experiments with rodents or other
mammalian species.121 Realising this vision would require extensive
development of test procedures and of approaches and methodologies
for interpreting and extrapolating the results to human populations.122
The reason why the report’s authors describe the proposed approach
as transformative is that it involves a different approach to identifying
health outcomes than that at the heart of traditional toxicology with its
dependence on in vivo testing. Rather than looking for “apical end
points,” that is, major changes observed in test subjects, an approach
that relies heavily on in vitro and in silico methods instead focuses on
“important biologic perturbations in key toxicity pathways.”123 Such
perturbations indicate a potential to cause adverse health outcomes
without demonstrating the actual health outcomes experimentally.
Initiatives such as this hold great promise for uncovering more
information and insight, more rapidly, into BPA and other known or
potential EDCs. Despite the immense investment of time and
resources into studying BPA, significant uncertainties remain about its
health effects. These uncertainties are partly due to the complexity of
human organisms and the multifaceted roles played by the endocrine
system. However, they also have to do with certain inherent limitations
of high-quality toxicology studies following conventional
methodologies and approaches, as well as the difficulties of
extrapolating from those studies to human organisms in light of the
kinds of exposures to which people are subject in the real world. When
one considers that BPA is not the only bisphenol, let alone chemical,
whose endocrine-disrupting properties are insufficiently understood,
the immensity of the challenge facing scientists and regulatory agencies
is more apparent. Thousands of new chemicals enter into commerce
annually, some of which are produced in high volumes and which,
therefore, may lead to high levels of exposure. Conventional in vivo
toxicity tests and risk assessments for all these chemicals would require
immense resources and take a good deal of time. The Canadian
government has sought to address this issue by requiring the
submission of data on new substances prior to their entry into the
Canadian market.124 Nevertheless, the need for rapid production of
121. Id. at 46–47.
122. Id. at 48.
123. Id.
124. Chemicals Management Plan Science Committee, Advancing Consideration of
Endocrine-disrupting Chemicals under the Canadian Environmental Protection Act, 1999,
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information remains pressing. This has led to tremendous interest
among researchers in academia, government, and industry in the
development of new approach methods (NAMs) to screen and
prioritise chemicals for their potentially adverse biological effects.
Government regulatory agencies and international organisations such
as the OECD are evaluating these new approaches and seeking to
determine how they contribute to priority setting and risk assessment.
One of the major attributes of NAMs is that they promote the 3 Rs by
reducing the number of animals used, replacing animal testing, and use
of refined methodology to decrease animal pain, distress and/or
suffering.125
A. In silico Methodology
In silico, or computer-based, toxicology can be used to analyse,
simulate, visualize, and predict the toxicity of a substance. This
methodology was developed for pharmacology, using information
from computational methods to screen chemicals for potential
beneficial or adverse effects to develop therapeutic drugs.126 The most
common in silico methods are quantitative structure-activity
relationship (QSAR) models.127 QSAR models employ algorithms to
predict toxicity based on the characteristics of chemicals.128 Large
datasets composed of previously-established biological information
regarding a particular molecule (the parent molecule) are used to
predict the biological activity of molecules with similar structures.129
The QSAR models can then be used to make predictions about the
biological effects of other chemicals that possess a given structural
feature.130 In addition, they may be used to enhance the robustness of
CANADA.CA (July 18-19, 2018) https://www.canada.ca/en/health-canada/services/chemicalsubstances/chemicals-management-plan/science-committee/meeting-records-reports/committeereport-july-18-19-2018.html (Can.).
125. Thomas Hartung, From Alternative Methods to a New Toxicology, EUR. J. PHAR.
BIOPHARM. 77, 338-349 (2011).
126. Luis G. Valerio Jr., In Silico Toxicology for the Pharmaceutical Sciences, TOXICOL.
APPL. PHARMACOL. 241, 356-370 (2009).
127. Arwa B Raies & Vladimir B Bajic, In Silico Toxicology: Computational Methods for the
Prediction of Chemical Toxicity, WILEY INTERDISC. REVS COMPUT. MOL. SCI. 6, 147-172 (2016);
Glenn J Myatt et al., In Silico Toxicology Protocols, REGUL TOXICOL PHARM 96, 1-17 (2018).
128. ALOK DHAWAN & SEOK KWON, IN VITRO TOXICOLOGY (2017); Giuseppina Gini,
QSAR Methods, in SILICO METHODS FOR PREDICTING DRUG TOXICITY (2016).
129. Dhawan & Kwon, supra note 128; Bas J. Blaauboer et al., The Integrated Use of
Alternative Methods in Toxicological Risk Evaluation - ECVAM Integrated Testing Strategies Task
Force Report 1, ALTERN. LAB. ANIM. 27, 229-237 (1999).
130. This is a very well-accepted view among toxicologists but by no means a unanimous one:
see, e.g., Bas J. Blaauboer & Melvin E. Andersen, The Need for a New Toxicity Testing and Risk
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in vitro and in vivo methods by making predictions regarding ideal
experimental conditions, thus improving the design of research
protocols.131 The OECD has developed a QSAR Toolbox, designed to
help users to fill data gaps, that is being used in a number of regulatory
programmes.132
Other in silico programmes are also being used to provide rapid
exposure estimates for thousands of chemicals.133 Targeted analyses are
used to detect chemicals that scientists expect to find in a sample.134
Non-targeted analyses, requiring sophisticated technologies and data
processing capacity, can be used to identify both known and unknown
chemicals in our environment.135 Finally, software packages have been
developed to estimate chemical concentrations in humans following
exposure.136 Many of the tools and resources that can be used to
estimate chemical exposures are available on the website of the US
EPA.137 Using these models and approaches, it is possible to make
useful predictions about exposure.
Despite certain limitations, the predictive capacity of in silico
models renders them a robust and economical complement to in vitro
and in vivo methods.138 Many regulatory agencies, including Health
Canada, are looking closely at these methodologies, but their

Analysis Paradigm to Implement REACH or Any Other Large Scale Testing Initiative, ARCH.
TOXICOL. 81, 385-387 (2007). Huanxiang Liu et al., QSAR Prediction of Estrogen Activity for a
Large Set of Diverse Chemicals under the Guidance of OECD Principles, CHEM. RES. TOXICOL.
19, 1540-1548 (2006).
131. Blaauboer & Andersen, supra note 131, at 386.
132. OECD
QSAR
Toolbox:
Frequently
Asked
Questions,
OECD,
https://www.oecd.org/env/ehs/risk-assessment/oecdqsartoolboxfrequentlyaskedquestions.htm
(last visited July 21, 2020).
133. Rapid
Chemical
Exposure
and
Dose
Research
(ExpoCast):
https://www.epa.gov/chemical-research/rapid-chemical-exposure-and-dose-research, U.S. EPA
(last visited July 21, 2020).
134. Heidelore Fiedler et al., A Critical Review of a Recommended Analytical and
Classification Approach for Organic Fluorinated Compounds with an Emphasis on Per- and
Polyfluoroalkyl Substances, INTEGR. ENVIRON. ASSESS. MANAG. 17, 331-351 (2021).
135. Jon R Sobus et al., Integrating Tools for Non-targeted Analysis Research and Chemical
Safety Evaluations at the US EPA, J. EXPO. SCI. ENV. EPID. 28, 411-426 (2018).
136. Katie Paul Friedman et al., Utility of In Vitro Bioactivity as a Lower Bound Estimate of
In Vivo Adverse Effect Levels and in Risk-Based Prioritization, TOXICOL. SCI. 173, 202-225
(2020).
137. United States Environmental Protection Agency (EPA), Rapid Chemical Exposure and
Dose
Research
https://www.epa.gov/chemical-research/rapid-chemical-exposure-and-doseresearch#1, (last visited Mar. 31, 2022).
138. OECD, GUIDELINES FOR THE TESTING OF CHEMICALS, https://www.oecdilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-1-physicalchemical-properties_20745753 (last visited May 18, 2020).
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widespread adoption to support regulatory decision-making depends
on a strong consensus among toxicologists that these methods are
robust and reliable.
B. In vitro Methods
In vitro toxicology may contribute important information on the
mechanism of action of a chemical – that is, how it produces or
contributes to particular health outcomes.139 Another advantage of in
vitro methods is their efficiency, resulting in savings in labour, cost, and
time.140 It is relatively easy to generate in vitro studies on a sufficiently
large number of chemicals over a wide range of concentrations to
produce confidence in the results. The caveat is that isolated cells
cannot capture everything that may occur in an intact tissue, organ,
animal, or person: the laboratory environment in which cell cultures
are maintained is dramatically different from the environment of a
living organism.141 Nevertheless, data derived from these in vitro
methods can be used to screen large batteries of chemicals, generating
large data sets and important insights into the effects of chemicals.
These screening techniques, known as high throughput and high
content screening (HTS, HCS) cell culture-based approaches, have
been used to assess the biological activity of thousands of chemicals.142
This initiative, known as Tox 21, proposes “a transformative paradigm
shift” from reliance on in vivo methods to the use of in silico and in
vitro methodologies.143
C. Organoids and Lower Species Animal Models
While analyses of the effects of a chemical in cell culture systems
provide valuable information, it is also important to understand how
cells interact. During in utero development, embryonic stem cells
differentiate to form all the organs in the body. Each organ is
composed of many distinct cell types, and their interactions are crucial.
Allowing cells in culture to grow either on their own, or in combination
with other cells derived from the same tissue, into a three dimensional
139. VA Baker, Endocrine Disrupters: Testing Strategies to assess Human Hazard, TOXICOL
IN VITRO, 15, 413-419 (2001); Marcel Leist et al., Adverse Outcome Pathways: Opportunities,
Limitations and Open Questions, ARCH. TOXICOL. 91, 3477-3505 (2017).
140. Id.
141. Id.
142. Abishankari Rajkumar et al., Elucidation of the Effects of Bisphenol A and Structural
Analogs on Germ and Steroidogenic Cells Using Single Cell High-Content Imaging. TOXICOL.
SCI. 180, 224-238 (2021).
143. See NAT’L RSCH. COUNCIL (NRC), supra note 115, at 46–47.
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structure known as an organoid, is leading to greater understanding of
importance of cell-cell communication in determining the effects of
exposure to a chemical. To capture the intricacy of these interactions
and their impact on organ functions, the US National Center for
Advancing Translational Sciences (NCATS) and collaborators are
focusing on the development of “tissues on a chip” to model the
structure and function of human organs.144 There is interest in the use
of these tissue chips known as organoids for toxicity testing and
prediction of drug safety.145
There is also interest in the possibility that toxicity testing in
simpler species provides valuable information that will bridge the gap
between in vitro and more traditional in vivo approaches. One of the
model species that is of interest to researchers and industry is
Caenorhabditis elegans, a worm that has many different organs yet is
small, easy to culture in a lab, and has a short life cycle.146 These
characteristics make C. elegans amenable to high-throughput
technologies. The zebrafish (Danio rerio) has also become very
popular as an experimental model, in part because its embryos are
transparent, facilitating the study of effects on development.147
D. Validation of NAMs
Tremendous international collaborative efforts are underway to
incorporate NAMs into regulatory decision-making.148 A range of
international and national organisations and agencies are in the process
of validating alternative methods.149 The validation process ensures
144. Tissue Chip Initiatives and Projects, NAT’L CTR. FOR ADVANCING TRANSLATIONAL
SCI.,
https://ncats.nih.gov/tissuechip/projects#:~:text=NCATS%2Dsupported%20researchers%20are
%20testing,and%20genetic%20changes%20in%20space (last visited Aug. 17, 2020).
145. Id.
146. Maxwell CK Leung et al., Caenorhabditis elegans: An Emerging Model in Biomedical
and Environmental Toxicology, TOXICOL SCI 106, 5-28 (2008).
147. Keng Po Lai et al., Zebrafish as the Toxicant Screening Model: Transgenic and Omics
Approaches. AQUAT TOXICOL 234,105813 (2021).
148. Reza Farmahin et al., Recommended Approaches in the Application of Toxicogenomics
to derive Points of Departure for Chemical Risk Assessment, ARCH TOXICOL 91, 2045-2065 (2017);
Robert J. Kavlock et al., Accelerating the Pace of Chemical Risk Assessment, CHEM RES TOXICOL
31, 287-290 (2018); Krewski et al., supra note 10.
149. European Centre for the Validation of Alternative Methods (EVCAM). Inter-Agency
Coordinating Committee on the Validation of Alternative Methods (ICCVAM). Japanese
Centre for the Validation of Alternative Methods (JaCVAM). Annamaria A Bottini et al.,
Optimisation of the Post-Validation Process: The Report and Recommendations of ECVAM
Workshop 67, ATLA-ALTERN. LAB. ANIM. 36, 353-366 (2008) (discussing the three initiatives
and some of their activities).
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that the alternative methods developed by researchers will be accepted
by regulatory agencies for safety testing and assessment purposes,
product approval, or classification.150 Test method validation refers to
a scientifically rigorous process of determining the reliability and
relevance of a particular test method and the extent to which a
procedure (or assay) using this method accurately measures or predicts
a biological effect.151 The correlation between the data obtained in
vivo, in vitro, and in silico should be consistent, reproducible, and easy
to access.152 Of course, the inherent limitation of the data obtained
using any of these approaches is that they may not be applicable to
humans due to potential differences in the molecules that are targeted
and the manner in which the chemicals are handled in humans, as
opposed to laboratory conditions or computer models.153 For instance,
the molecules or pathways that are targeted in humans may not be
present in animals or cells. Further, the way the chemical is handled in
the body may increase or decrease its toxicity, since metabolism may
render the substance harmless or increase its activity. In addition,
different means of eliminating chemicals will affect the body’s
response. Perhaps it is not surprising that the effects produced by a
chemical, such as BPA, may depend on the test system (in silico, in
vitro, or in vivo) and that this will need to be considered in interpreting
the data. In addition, BPA exposure may produce various integrated
biological outcomes at different periods of life. This is not unique to
BPA. The development of pathways, known as Adverse Outcome
Pathways,154 that “describe a logical sequence of causally linked events
at different levels of biological organisation, which follows exposure to
a chemical and leads to an adverse health effect in humans or wildlife”
is one of the goals of the OECD.155 It is anticipated that this type of
“chemical risk assessment based on mechanistic reasoning” will be very
useful in allowing researchers and regulators to connect the findings
from different test systems with health outcomes.156
150. Helena Kandárová & Silvia Letašiová, Alternative Methods in Toxicology: Pre-Validated
and Validated Methods, INTERDISCIP. TOXICOL. 4, 107-113 (2011).
151. Id.
152. Id.
153. Coady KK. et al., Current Limitations and Recommendations to improve Testing for the
Environmental Assessment of Endocrine Active Substances. INTEGR. ENVIRON. ASSESS. MANAG.
13, 302-316 (2017).
154. Matthieu Mondou et al., Envisioning an International Validation Process for New
Approach Methodologies in Chemical Hazard and Risk Assessment, ENVIRON. ADVANCES 4,
100061 (2021).
155. Id.
156. USERS’ HANDBOOK SUPPLEMENT TO THE GUIDANCE DOCUMENT FOR DEVELOPING
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The acceptance of new approaches and methodologies by
scientists can be a slow and sometimes difficult process. Scientists must
have grounds for confidence in those methodologies; this requires
having extensive experience with their accuracy and prediction value.
Only then can a substantial body of evidence be developed that is
sufficiently robust, reliable, and relevant to generate confidence. Once
a certain degree of consensus around a novel approach or methodology
has been arrived at by scientists, the truly hard work begins: namely,
the post-validation process, involving acceptance of scientifically
approved methodologies by regulatory agencies.157 As Annamaria
Bottini and colleagues note, regulatory agencies often take a
conservative approach to studying chemical risk, with the result that
accepted methods for determining hazard and risk can come to be
“frozen in time.”158 One very important reason for this conservatism is
that public safety depends on the scientific inputs that contribute to
regulatory decision-making, inputs that depend heavily on
methodology.159 In addition, regulators are themselves not always
particularly knowledgeable about methodological developments.160
The universal validity of scientific knowledge should militate in
favour of take-up of scientific progress on methodology across the
globe, at roughly the same rate from one region or state to another.
But this does not necessarily happen,161 in part because of different
cultural, social, economic, and political factors in different states. Some
important differences include varying levels of risk aversion, different
degrees of aversion to different types of risk, varying levels of
confidence of political authorities and members of the public in
science, and different understandings of what constitutes an
appropriate division of labour among scientific experts and other
participants in decision-making. Be that as it may, a degree of global
consensus on methodologies and approaches for toxicity testing is
necessary to avoid patchworks of standards that impede trade flows, as
well as lack of confidence in regulatory authorities beyond one’s
AND
ASSESSING
ADVERSE
OUTCOME
PATHWAYS,
OECD,
https://www.oecdilibrary.org/environment/users-handbook-supplement-to-the-guidance-document-fordeveloping-and-assessing-adverse-outcome-pathways_5jlv1m9d1g32-en (last visited July 21,
2020).
157. Bottini et al., supra note 149, at 353.
158. Annamaria A. Bottini et al., Food for Thought. . . on Globalisation of Alternative
Methods, ALTEX 24, 255-269 (2007).
159. Id.; Bottini et al., supra note 149, at 361.
160. Id.
161. Bottini et al., supra note 158, at 255.
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borders. For these and other reasons, various international
organisations and interjurisdictional bodies and processes have been
tasked with harmonising, or at least coordinating, the scientific
validation of testing methodologies as a means of promoting the
widespread take-up of a common suite of approaches and methods
across the globe. Chief among these organisations is the OECD.
Regional and national bodies have also been created explicitly to
promote the validation of alternative methods in Canada,162 Europe,163
the United States,164 and Japan.165
In vetting new methodologies, regulatory agencies look to the
usefulness and limitations of the test method. They seek to determine
the method’s reliance, meaning the reproducibility of results from a
test within and across laboratories and over time, when performed
using the same standardized protocol, and relevance, meaning the
usefulness of results in light of the purposes and objectives pursued by
testing.166 Recently, several alternative methods (the direct peptide
reactivity assay, Keratinases, and the human cell line activation tests)
have been validated for use in predicting the ability of chemicals to
elicit an allergic reaction in skin.167
V.

CONCLUDING REMARKS

The challenges that known and suspected EDCs pose to political
authorities are significant. Many of the health effects that these
substances produce, or are suspected to produce, are serious. Gaining
insights into their impact is arduous, time-consuming, and resourceintensive. Even for substances such as BPA that have received an
enormous amount of scientific and regulatory scrutiny, knowledge
gaps and scientific controversies remain significant. NAMs hold
immense promise, but many of these methodologies remain to be
162. CANADIAN CENTRE FOR ALTERNATIVES TO ANIMAL MODELS (CCAAM);
CANADIAN CENTRE FOR THE VALIDATION OF ALTERNATIVE METHODS (CaCVAM).
163. EUROPEAN CENTRE FOR THE VALIDATION OF ALTERNATIVE METHODS (EVCAM).
164. INTER-AGENCY COORDINATING COMMITTEE ON THE VALIDATION OF ALTERNATIVE
METHODS (ICCVAM).
165. JAPANESE CENTRE FOR THE VALIDATION OF ALTERNATIVE METHODS (JaCVAM)
(discussing these three initiatives and some of their activities); see also Bottini et al., supra note
149.
166. Niladri Basu et al., EcoToxChip: A Next generation Toxicogenomics Tool for Chemical
Prioritization and Environmental Management, ENVIRON. TOXICOL. CHEM. 38, 279-288 (2019);
Leon H. Bruner et al., Validation of Alternative Methods for Toxicity Testing, TOXICOL. IN VITRO,
10, 479-501 (1996).
167. Joyce VB. Borba et al., Pred-Skin: A Web Portal for Accurate Prediction of Human Skin
Sensitizers, CHEM. RES. TOXICOL. 34, 258-267 (2021).
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validated. Regulators interested in exploring and expanding reliance
on NAMs face risks. Moving from well-understood toxicological
methodologies, with which scientists, regulators, and industry have
many decades of experience, to much newer and less familiar
methodologies is a difficult process involving complex communications
between science and policy to foster confidence and trust, and further
confidence-building work with stakeholders, including industry and
civil society.
As we have seen, the regulation of BPA by Canada and other
states takes place against a backdrop of scientific uncertainty and
controversy. It is clearly not up to government agencies to arbitrate
these controversies, but at the same time they cannot simply wait for
them to be resolved. It may be that increasing experience with NAMs
will promote their broader acceptance within scientific communities,
and that regulatory authorities and stakeholders will themselves learn
to trust in the capacity of these methodologies to relay relevant and
reliable information on risk. However, as Cynthia Hardy and Steve
Maguire note, the shift from one approach for generating insight into
risks posed by chemicals to another approach itself generates an array
of different types of risks for regulatory agencies, industry, civil society
organisations and many other actors that either make representations
regarding safety on the basis of particular bodies of knowledge or rely
on those representations in pursuing their own activities.168
The Canadian regulatory decision on BPA was made at a
particularly turbulent time in the science of endocrine disruption.
Regulatory agencies in Canada and other jurisdictions must navigate a
context which is rendered more complex with ongoing developments
in toxicology and endocrinology. Our aim in this paper has been to
shed light on the regulatory decision-making process and the broader
scientific context in which it is embedded, and to draw attention to
ongoing scientific developments of great relevance to the regulation of
EDCs.

168. Maguire & Hardy, supra note 57.

